THE THERAPEUTIC USE OF CANNABIDIOL (CBD) IN ANXIETY DISORDERS AND DEPRESSION
DOI:
https://doi.org/10.47820/recima21.v4i1.4049Keywords:
Endocannabinoid, anxiety, anxiogenics, CBD, THC and cannabinoids.Abstract
The present work addresses the subject of the therapeutic use of cannabidiol (CBD) in the treatment of anxiety and depression disorders. Through a literature review, we seek to provide a comprehensive understanding of the subject, considering the historical context of the Cannabis plant, the characteristics of cannabidiol, scientific evidence that proves its effectiveness and data that make its safety clear. The objective of the present study is to analyze and understand, through a literary search, the mechanism of action and its effects on anxiety, which in turn has an impact on depression, defining from a literary analysis whether cannabidiol is effective or not. not in the treatment of anxiety disorders and depression.The review covers clinical studies, meta-analyses and systematic reviews, providing a comprehensive overview of the most relevant research on the topic. This analysis allows for a more accurate understanding of the benefits and limitations of using CBD in the treatment of these disorders. Through this literature review, the work contributes to the understanding of the therapeutic use of cannabidiol in the context of anxiety and depression disorders and whether it is safe.
Downloads
References
ADAMS, R. Estrutura do canabidiol, um produto isolado do extrato de maconha de cânhamo selvagem de Minnesota. Journal of the American Chemical Society, v. 62, n. 1, p. 196-200, 1940.
ALMEIDA, R. T. et al. Efeitos do canabidiol no transtorno de ansiedade generalizada: um estudo piloto. Revista Brasileira de Psiquiatria, 2019.
BANDELOW, B. et al. Eficácia de tratamentos para transtornos de ansiedade: uma meta-análise. International Clinical Psychopharmacology, v. 30, n. 4, p. 183-192, 2015.
BERGAMESCHI, M. M. et al. Cannabidiol reduces anxiety in social phobia patients. Neuropsychopharmacology, v. 36, n. 6, p. 1219-1226, 2011.
BLUMBERG, M.J. et al. Procognitive Effects of Antidepressants and Other Therapeutic Agents in Major Depressive Disorder: A Systematic Review. The Journal of Clinical Psychiatric, v. 81, 2020.
BLESSING, E. M. et al. Cannabidiol as a potential treatment for anxiety disorders. Neurotherapeutics, v. 12, n. 4, p. 825-836, 2015.
CAMPOS, A. C. et al. Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders. Philosophical Transactions of the Royal Society B: Biological Sciences, v. 367, n. 1607, p. 3364-3378, 2012.
CAMPOS, A. C.; Fogaça, M. V.; Guimarães, F. S. Cannabidiol, neuroprotection and neuropsychiatric disorders. Pharmacological Research, v. 119, p. 1-16, 2018.
CAMPOS, A. C.; Guimarães, F. S.; Zuardi, A. W. 5-HT1A receptors are involved in the cannabidiol-induced attenuation of behavioural and cardiovascular responses to acute restraint stress in rats. British Journal of Pharmacology, v. 166, n. 1, p. 202-212, 2012.
CRIPPA, J. A. S. et al. Translational Investigation of the Therapeutic Potential of Cannabidiol (CBD): Toward a New Age. Frontiers in Immunology, v. 9, p. 2009, 2018.
CRIPPA, J. A. et al. Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. Journal of Psychopharmacology, v. 25, n. 1, p. 121-130, 2011.
CUIJIPERS, P. et al. A eficácia da psicoterapia e farmacoterapia no tratamento de transtornos depressivos e de ansiedade: uma meta-análise de comparações diretas. World Psychiatry, v. 13, n. 3, p. 318-328, 2014.
ETTMAN, C. K. et al. Prevalência de sintomas depressivos em adultos nos EUA antes e durante a pandemia de COVID-19. Psychiatry Research, 2021.
GANJI, O. et al. The growing body of evidence on the therapeutic potential of cannabidiol: A comprehensive review of the literature. Front. Pharmacol., v. 12, p. 1-19, 2021.
GARCIA-GUTIÉRREZ, M. S. et al. Cannabidiol: A Potential New Alternative for the Treatment of Anxiety, Depression, and Psychotic Disorders. Biomolecules, v. 10, n. 11, p. 1575, 2020.
HANÉY, M. et al. Oral cannabidiol does not alter the subjective, reinforcing or cardiovascular effects of smoked cannabis. Neuropsychopharmacology, v. 41, n. 8, p. 1974-1982, 2016.
HURD, Y. L. et al. Canabidiol for the reduction of cue-induced craving and anxiety in drug-abstinent individuals with heroin use disorder: A randomized, double-blind, placebo-controlled trial. American Journal of Psychiatry, 2019.
IFFLAND, K.; Grotenhermen, F. An update on safety and side effects of cannabidiol: A review of clinical data and relevant animal studies. Cannabis and Cannabinoid Research, v. 2, n. 1, p. 139-154, 2017.
KAPAN, M. R.; Plath, D. L. The global diffusion of cannabis: A growing challenge. Bulletin ofthe World Health Organization, v. 97, n. 9, p. 596-597, 2019.
KAZDIN, A. E.; Blase, S. L. Reiniciando a pesquisa e a prática em psicoterapia para reduzir o fardo dos transtornos mentais. Perspectives on Psychological Science, v. 6, n. 1, p. 21-37, 2011.
KESSLER, R. C. et al. Prevalence, severity, and comorbidity of twelve-month DSM-IV disorders in the National Comorbidity Survey Replication (NCS-R). Archives of General Psychiatry, v. 62, n. 6, p. 617-627, 2005.
KOGAN, N. M.; Mechoulam, R. Canabinoidesnasaúde e nadoença. Dialogues in Clinical Neuroscience, v. 9, n. 4, p. 413-430, 2007.
LATTANZI, S. et al. Efficacy and safety of cannabidiol in epilepsy: A systematic review and meta-analysis. Drugs, 2018.
LINGE, R. et al. Cannabidiol induces rapid-acting antidepressant-like effects and enhances cortical 5-HT/glutamate neurotransmission: Role of 5-HT1A receptors. Neuropharmacology, v. 103, p. 16-26, 2016.
LIMA-OJEDA, J. M. et al. Disadvantages and Potential Side Effects of Antidepressant Treatment. Frontiers in Psychiatry, v. 11, article 686, 2020.
LINGE, R. et al. Influence of single and repeated cannabidiol administration on emotional behavior and markers of cell proliferation and neurogenesis in non-stressed mice. BrainResearch Bulletin, v. 143, p. 142-149, 2018.
MCPARTLAND, J. M.; Russo, E. B. Cannabis e extratos de cannabis: maior do que a soma de suas partes? Journal of Cannabis Therapeutics, v. 1, n. 3-4, p. 103-132, 2001.
MCPARTLAND, J. M. et al. Canabidiol e Delta(9)-tetrahydrocannabivarin são moduladores negativos do sistema endocanabinoide? Uma revisão sistemática. British Journal of Pharmacology, v. 172, n. 3, p. 737-753, 2015.
MCGUIGAN, M. Cannabinoids. In: GOLDFRANK, L. R.; HOFFMAN, R. S. et al. Goldfrank’s Toxicologic Emergencies. 9 ed. New York: McGraw-Hill, 2010.
MORESCO, R. M. Towards in vivo imaging of functionally active 5-HT1A receptors in schizophrenia: concepts and challenges. TranslationalPsychiatryNature, 2021.
PERTWEE, R. G. A farmacologia dos receptores canabinoides e seus ligantes: uma visão geral. International Journal of Obesity, v. 30, supl. 1, p. S13-S18, 2006.
PIERINI, M. M. et al. Anxiolytic effect of cannabidiol derivatives in the elevated plus maze. Genes, Brain and Behavior, v. 6, n. 4, p. 479-485, 2007.
RUSSO, E. B. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br. J Pharmacol, v. 163, n. 7, p. 1344-1364, 2011.
SALES, A. J. et al. Cannabidiol induces rapid and sustained antidepressant-like effects through increased BDNF signaling and synaptogenesis in the prefrontal cortex. Molecular Neurobiology, v. 56, n. 2, p. 1070-1081, 2019.
SCHIAVON, A. P. et al. Influence of single and repeated cannabidiol administration on emotional behavior and markers of cell proliferation and neurogenesis in non-stressed mice. Brain Research Bulletin, v. 143, p. 142-149, 2018.
SAITO, V. M.; Wotjak, C. T.; Moreira, F. A..Exploraçãofarmacológica do sistema endocanabinoide: novas perspectivas para o tratamento de transtornos de ansiedade e depressão. Revista Brasileira de Psiquiatria, p. 57-514, 2010.
SHANNON, S. et al. Cannabidiol in anxiety and sleep: A large case series. The Permanente Journal, 2019.
SILVEIRA Filho, N. G.; Tufik, S. Comparative effects between cannabidiol and diazepam on neophobia, food intake and conflict behavior. Res Commun Psychol Psychiatry Behav, v. 6, n. 1, p. 1-10, 1981.
SMITH, J. K.; Smith, A. B. Endocannabinoid signaling and regulation of neuroinflammation. Journal of Neuro inflammation, v. 15, 2018.
SOLOMON, M. A. et al. Efeitos farmacológicos e clínicos da cannabis medicinal. Pharmacotherapy, v. 35, n. 3, p. 195-209, 2015.
SUGAWARA, C.; Bussmann, R. W. O uso do canabidiol (CBD) no tratamento da ansiedade e da depressão: uma revisão sistemática. Revista Brasileira de Plantas Medicinais, v. 22, n. 1, p. 198-204, 2020.
XU, Z.; Müller, M. B.; Richter, S. H. Challenges and Limitations in Antidepressant Treatment: Do We Need to Broaden the Scope of Drug Discovery and Development Neuroscience. Biobehavioral Reviews, v. 55, p. 522-537, 2015.
YARIBEYGI, H. et al. The impact of stress on body function: A review. Excli Journal, v. 16, p. 1057-1072, 2017.
ZANELATI, T. V. et al. Antidepressant-like effects of cannabidiol in mice: Possible involvement of serotonergic receptors. Brain Research Bulletin, v. 81, n. 4-5, p. 463-470, 2010.
ZUARDI, A. W. et al. Curva de dose-resposta em forma de U invertido do efeito ansiolítico do canabidiol durante fala em público na vida real. Frontiers in Pharmacology, v. 8, 2017.
ASSOCIAÇÃO BRASILEIRA DE NORMAS TÉCNICAS.NBR 6023: informação e documentação: referências: elaboração. Rio de Janeiro, 2018.
Downloads
Published
Issue
Section
Categories
License
Copyright (c) 2023 RECIMA21 - Revista Científica Multidisciplinar - ISSN 2675-6218
This work is licensed under a Creative Commons Attribution 4.0 International License.
Os direitos autorais dos artigos/resenhas/TCCs publicados pertecem à revista RECIMA21, e seguem o padrão Creative Commons (CC BY 4.0), permitindo a cópia ou reprodução, desde que cite a fonte e respeite os direitos dos autores e contenham menção aos mesmos nos créditos. Toda e qualquer obra publicada na revista, seu conteúdo é de responsabilidade dos autores, cabendo a RECIMA21 apenas ser o veículo de divulgação, seguindo os padrões nacionais e internacionais de publicação.
